Enhanced Protection against Cytokine- and Fatty Acid-induced Apoptosis in Pancreatic Beta Cells by Combined Treatment with Glucagon-like Peptide-1 Receptor Agonists and Insulin Analogues

Abstract

We recently showed that insulin analogues exhibit a beta-cell protective function. The aim of this study was to test if the anti-apoptotic activity of GLP-1 agonists and insulin analogues is mediated by different pathways and if combined treatment may provide augmented protection against beta-cell death. Incubation of INS-1 cells with cytokines or fatty acids increased the number of apoptotic cells and caspase 3 activity, which was reduced by pretreatment with GLP-1 and its receptor agonists exendin-4 and AVE0010 by 50-60%. Similar effects (about 40% reduction) were observed after pretreatment with several insulin analogues. Combined treatment revealed additive activity and resulted in prevention of both cytokine- and fatty acid-induced apoptosis by up to 80%. No acute Akt-phosphorylation in response to GLP-1 receptor agonists could be observed, however, it became detectable after 24-hour stimulation. Gene silencing of Akt2 increased cytokine-induced apoptosis 2-fold. Under these conditions the beta-cell protective activity of AVE0010 remained completely unaltered. We show here that the anti-apoptotic activity of GLP-1 and its receptor agonists AVE0010 and exendin-4 is enhanced by addition of insulin analogues and that the anti-apoptotic action of GLP-1 mimetics is mostly unrelated to Akt2 signaling. It is suggested that combination of GLP-1 receptor agonists and insulin analogues, specifically insulin glargine, may represent a new therapeutic option for preservation of beta-cell mass in type 2 diabetic patients.

Key words

INS-1 cells - cytokines - apoptosis - glucagon-like peptide-1 - insulin analogues - Akt - siRNA

References

• 1 Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.  Endocr Rev. 1995;  16 390-410
• 2 Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells.  Endocrinology. 1992;  130 159-166
• 3 Nauck MA, Heimesaat MM, Behle K. et al . Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.  J Clin Endocrinol Metab. 2002;  87 1239-1246
• 4 Nauck MA, Niedereichholz U, Ettler R. et al . Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.  Am J Physiol. 1997;  273 E981-E988
• 5 Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.  J Clin Invest. 1998;  101 515-520
• 6 Gutzwiller JP, Goke B, Drewe J. et al . Glucagon-like peptide-1: a potent regulator of food intake in humans.  Gut. 1999;  44 81-86
• 7 Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway.  Endocrinology. 2003;  144 1444-1455
• 8 Farilla L, Hui H, Bertolotto C. et al . Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.  Endocrinology. 2002;  143 4397-4408
• 9 Mellado-Gil JM, Aguilar-Diosdado M. High glucose potentiates cytokine- and streptozotocin-induced apoptosis of rat islet cells: effect on apoptosis-related genes.  J Endocrinol. 2004;  183 155-162
• 10 Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.  J Biol Chem. 2003;  278 471-478
• 11 Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells.  Diabetologia. 2004;  47 478-487
• 12 Li L, El Kholy W, Rhodes CJ, Brubaker PL. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B.  Diabetologia. 2005;  48 1339-1349
• 13 Jhala US, Canettieri G, Screaton RA. et al . cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2.  Genes Dev. 2003;  17 1575-1580
• 14 Kwon G, Pappan KL, Marshall CA, Schaffer JE, MacDaniel ML. cAMP Dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP-guanine nucleotide exchange factor-dependent pathways in beta-cells.  J Biol Chem. 2004;  279 8938-8945
• 15 Garofalo RS, Orena SJ, Rafidi K. et al . Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta.  J Clin Invest. 2003;  112 197-208
• 16 Chen WS, Xu PZ, Gottlob K. et al . Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene.  Genes Dev. 2001;  15 2203-2208
• 17 Castrillo A, Bodelon OG, Bosca L. Inhibitory effect of IGF-I on type 2 nitric oxide synthase expression in Ins-1 cells and protection against activation-dependent apoptosis: involvement of phosphatidylinositol 3-kinase.  Diabetes. 2000;  49 209-217
• 18 Wrede CE, Dickson LM, Lingohr MK, Briaud I, Rhodes CJ. Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1).  J Biol Chem. 2002;  277 49676-49684
• 19 Rakatzi I, Seipke G, Eckel J. LysB3, GluB29 insulin: a novel insulin analog with enhanced beta-cell protective action.  Biochem Biophys Res Commun. 2003;  310 852-859
• 20 Burks DJ, White MF. IRS proteins and beta-cell function.  Diabetes. 2001;  50 ((Suppl 1)) S140-S145
• 21 Lingohr MK, Dickson LM, Wrede CE. et al . Decreasing IRS-2 expression in pancreatic beta-cells (INS-1) promotes apoptosis, which can be compensated for by introduction of IRS-4 expression.  Mol Cell Endocrinol. 2003;  209 17-31
• 22 Trumper K, Trumper A, Trusheim H, Arnold R, Goke B, Horsch D. Integrative mitogenic role of protein kinase B/Akt in beta-cells.  Ann NY Acad Sci. 2000;  921 242-250
• 23 Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.  J Pharmacol Exp Ther. 2003;  307 490-496
• 24 Asfari M, Janjic D, Meda P, Li GD, Halban PA, Wollheim CB. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell-lines.  Endocrinology. 1992;  130 167-178
• 25 Kutlu B, Cardozo AK, Darville MI. et al . Discovery of gene networks regulating cytokine-induced dysfunction and apoptosis in insulin-producing INS-1 cells.  Diabetes. 2003;  52 2701-2719
• 26 Hoorens A, Van de CM, Kloppel G, Pipeleers D. Glucose promotes survival of rat pancreatic beta cells by activating synthesis of proteins which suppress a constitutive apoptotic program.  J Clin Invest. 1996;  98 1568-1574
• 27 Katome T, Obata T, Matsushima R. et al . Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions.  J Biol Chem. 2003;  278 28312-28323
• 28 Ahren B, Schmitz O. GLP-1 Receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.  Horm Metab Res. 2004;  36 867-876
• 29 Gallwitz B. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.  Diabetes Technol Ther. 2005;  7 651-657
• 30 Goke R, Fehmann HC, Linn T. et al . Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.  J Biol Chem. 1993;  268 19650-19655
• 31 Bregenholt S, Moldrup A, Blume N. et al . The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.  Biochem Biophys Res Commun. 2005;  330 577-584
• 32 Kukreja A, Maclaren NK. Autoimmunity and diabetes.  J Clin Endocrinol Metab. 1999;  84 4371-4378
• 33 Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus.  Mayo Clin Proc. 2003;  78 447-456
• 34 Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.  Diabetes. 2003;  52 102-110
• 35 Heine RJ, Gaal LF Van, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.  Ann Intern Med. 2005;  143 559-569
• 36 Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.  Endocrinology. 2004;  145 2653-2659
• 37 Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells.  Diabetologia. 1999;  42 856-864
• 38 Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation.  Diabetes. 2001;  50 2237-2243
• 39 Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor.  Diabetes. 2003;  52 124-132
• 40 Park S, Dong X, Fisher TL. et al . Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function.  J Biol Chem. 2006;  281 1159-1168
• 41 Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts.  Genes Dev. 1999;  13 2905-2927
• 42 Holst LS, Mulder H, Manganiello V. et al . Protein kinase B is expressed in pancreatic beta cells and activated upon stimulation with insulin-like growth factor I.  Biochem Biophys Res Commun. 1998;  250 181-186

Correspondence